NCT06705803Recruiting
Prostate Ablation Registry and Database for Information, Surveillance, and Evaluation (PARADISE)
Source: ClinicalTrials.gov · Last updated 2 Feb 2026
Brief summary (registry, in English)
Prostate cancer (PCa) is the most commonly diagnosed non-cutaneous cancer of men in the world. In 2023 alone, it is estimated that 288,300 US men will be diagnosed with prostate cancer and 34,700 will die from the disease despite the approval of multiple systemic agents. Due to advances in screening and imaging technology, PCa is now detected much earlier in its disease course. Prostate gland ablation for prostate cancer might provide the option for a "middle" ground between active surveillance (AS) and radical therapy by destroying prostate cancer in a minimally invasive or non-invasive fashion and thus limiting the morbidity. This treatment strategy is increasingly being offered to patients due to low morbidity but the data on long term oncologic efficacy and side effect profile is lacking for such a treatment strategy. The purpose of this study is to create a database and prospective registry for data collection on patients with prostate cancer undergoing prostate ablation for the management of prostate cancer. Patients with biopsy-proven prostate cancer of any Gleason Grade will be entered into the registry as long as prostate ablation is used as the prostate cancer management modality. Historical data from 2017 to the present time will be added through chart review. Current and future patient data will be collected through chart review during the subject's clinical care. Only data available in the electronic medical record will be collected and no additional data will be collected for research purposes. No biospecimens will be collected, and there are no physical risks from study participation.
- Status (registry)
- Recruiting
- Study type
- Observational
- Enrollment
- 3000 (estimated)
- First submitted
- 14 Nov 2024
- Start date
- 21 Jun 2024
- Primary completion date
- 30 Jun 2029
- Lead sponsor
- University of Chicago
- Diseases
- Prostate cancer
- NCT number
- NCT06705803
What you commit to
- Study type: Observational
- Planned participants: 3000
- From 21 Jun 2024 to the primary completion date, 30 Jun 2029
- 2 sites in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Age
- Under 21 Years of age.
Who the study is looking for
- Male sex
- ≥22 years of age
- Histologic diagnosis of prostate cancer
- Scheduled to undergo or have already undergone ablation of the prostate as part of routine clinical care or any ongoing clinical trials
- Prostate ablation performed with any of the following energy sources: cryotherapy, high-intensity focused ultrasound, irreversible electroporation, laser, microwave, radiofrequency ablation, or photodynamic therapy. Newer methods and instrumentation continue to be developed to ablate tissue, and these energy sources can be entered into the registry as clinical use begins
Age in the registry: 22 years to - · Sex: Male · Does not accept healthy volunteers
Sites (2)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| The University of Cinncinatti Coordinator of this site? Confirm its status | Cincinnati | United States | Recruiting |
| The University of Chicago Coordinator of this site? Confirm its status | Hyde Park | United States | Recruiting |
This page is information, not medical advice. Discuss any trial with your doctor.